Immuno-oncology research and the subsequent development of immunotherapies continue to progress rapidly. We now can look ahead to new developments in cancer immunotherapy which might provide the basis of tomorrow’s cancer treatments. At present, we are living a new chapter with the tremendous advancement of the tumor immune-biology aiming at making one day the word “cure” a reality for cancer patients. Personalized immunotherapy based on individual genetic, molecular and immune profiling, as well as genome guided profiling, is in this regard a goal potentially achievable in the near future.

This meeting will thus bring together key actors in the field of cancer immunotherapy that will cast novel research aims in various fields such as the immunosuppressive tumor microenvironment, the mutanome, the microbiota and metabolism. This should provide updates on ongoing therapeutical approaches in immune checkpoint therapies, CAR-T cells and cancer vaccines, and discussions on development of novel and objectively evidence-based efficient cancer immunotherapies.

The goal of this Conference is to bring together researchers, biologists, clinicians and pharmaceutical partners under a unique comprehensive workshop to discuss present and future perspectives in this exciting field.

**Organizing Committee:** Salem Chouaib and Claude Leclerc

**Scientific Committee:** Jean-Pierre Abastado, Marc Bonneville, Jean-Yves Blay, Christine Chomienne, Patrice Debré, Jean-Jacques Fournié, Frédérique Nowak, Vassili Soumelis, Daniel Olive, Eric Tartour, François Vallette.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Registration</td>
</tr>
<tr>
<td>09:00</td>
<td><strong>Welcome</strong></td>
</tr>
<tr>
<td></td>
<td>Claude Leclerc and Salem Chouaib, Organizing Committee</td>
</tr>
<tr>
<td></td>
<td><strong>Introduction</strong></td>
</tr>
<tr>
<td></td>
<td>Norbert Ifrah (Institut national du cancer, Boulogne-Billancourt)</td>
</tr>
<tr>
<td></td>
<td>Christine Chomienne (Aviesan’s Cancer Institute, Paris &amp; Institut national du cancer, Boulogne-Billancourt)</td>
</tr>
<tr>
<td>09:15</td>
<td><strong>Keynote lecture</strong></td>
</tr>
<tr>
<td></td>
<td>Chairmen: Jean-Yves Blay (Centre Léon Bérard, Lyon) and Alexander Eggermont (Gustave Roussy, Villejuif)</td>
</tr>
<tr>
<td></td>
<td>Giorgio Trinchieri (NIH-NCI, Bethesda)</td>
</tr>
<tr>
<td></td>
<td>Inflammation and tumor microenvironment</td>
</tr>
<tr>
<td>10:00</td>
<td><strong>Session 1: Immune checkpoints and costimulatory molecules</strong></td>
</tr>
<tr>
<td></td>
<td>Chairmen: Eric Vivier (CIML, Marseille) and Salem Chouaib (Gustave Roussy, Villejuif)</td>
</tr>
<tr>
<td></td>
<td>10:00-10:30 Alexander Eggermont (Gustave Roussy, Villejuif)</td>
</tr>
<tr>
<td></td>
<td>Melanoma serves as the model for solid tumors</td>
</tr>
<tr>
<td></td>
<td>10:30-11:00 Jacques Cadranel (Hôpital Tenon, Paris)</td>
</tr>
<tr>
<td></td>
<td>Is there a place for ICI in the context of oncogenic addiction?</td>
</tr>
<tr>
<td>11:00</td>
<td><strong>Coffee Break</strong></td>
</tr>
</tbody>
</table>
The French National Cancer Institute (INCa) &
The French National Alliance for Life Sciences and Health (Aviesan-ITMO Cancer)
present

**Session 1: Immune checkpoints and costimulatory molecules**
Chairmen: Eric Vivier (CIML, Marseille) and Salem Chouaib (Gustave Roussy, Villejuif)

- **11:30-12:00** Yong-Jun Liu (Sanofi, Cambridge)
  Multi-targeting for cancer immunotherapy

- **12:00-12:30** Bernard Escudier (Gustave Roussy, Villejuif)
  Immunotherapy in kidney cancer: current situation and challenges

**12:30** Lunch

**14:00** Session 2: Tumor microenvironment
Chairwoman/man: Catherine Sautès-Fridman (Centre de recherche des Cordeliers, Paris) and Vassili Soumelis (Institut Curie, Paris)

- **14:00-14:30** Gregg Semenza (John Hopkins University, Baltimore)
  Hypoxia-inducible factors endow cancer cells with the capacity for tumor initiation and immune evasion

- **14:30-15:00** Benoit van den Eynde (Ludwig Institute for Cancer Research, Brussel)
  Combating immunosuppression in the tumor microenvironment

- **15:00-15:30** Sergio Abrignani (INGM, Milan)
  Defining molecular identity of intratumoral T cells to design better cancer immunotherapies

- **15:30-16:00** François Ghiringhelli (Centre de Recherche Inserm-LNC, Dijon)
  Chemotherapy and anti-cancer immune response: how to use cytotoxic agent to improve efficacy of immune-oncologic drugs?
16:00  Coffee Break

16:30  **Session 3: Novel approaches to analyze tumor microenvironment**
      **Chairmen:** Daniel Olive (CRCM, Marseille) and Pierre Saintigny (CRCL, Lyon)

      ▶ 16:30-17:00 Janis Marie Taube (John Hopkins University, Baltimore)
          PD-L1 and associated biomarkers: What’s new and what’s next?

      ▶ 17:00-17:30 Jérôme Galon (Centre de recherche des Cordeliers, Paris)
          Immune contexture and immunoscore in the era of cancer immunotherapy

**November 28, 2017**

09:00  **Keynote lecture**
      **Chairmen:** Eric Tartour (HEGP, Paris) and Jean-Christophe Bories (Hôpital Saint Louis, Paris)

      ▶ Carl H. June (Perelman School of Medicine, University of Pennsylvania)
          T Cell therapy for Cancer

09:45  **Session 4: Cancer vaccines**
      **Chairwoman/man:** Fathia Mami Chouaib (Gustave Roussy, Villejuif) and Jean-Jacques Fournié (Inserm, Toulouse)

      ▶ 09:45-10:15 Sergio Quezada (UCL Cancer Institute, London)
          Deciphering immune regulation within tumors

      ▶ 10:15-10:45 Lelia Delamarre (GRME-South San Francisco)
          Harnessing mutations for personalized cancer vaccine
The French National Cancer Institute (INCa) & The French National Alliance for Life Sciences and Health (Aviesan-ITMO Cancer) present

**cancer IMMUNOTHERAPY 2017**
**PROGRESSES & CHALLENGES**

10:45 **Coffee Break**

11:15 **Session 5: Cancer vaccines/Adoptive T cell immunotherapy/Oncolytic viruses**

Chairwoman/man: Claude Leclerc (Institut Pasteur, Paris) and Aurélien Marabelle (Gustave Roussy, Villejuif)

- 11:15-11:45 Sjoerd van der Burg (Leiden University Medical Center, Leiden)
  Chemotherapy to improve the therapeutic efficacy of cancer vaccines

- 11:45-12:15 Justin Eyquem (Memorial Sloan Kettering Cancer Center, New-York)
  Precision T cell engineering to advance CAR therapy

- 12:15-12:45 Eric Quemeneur (Transgène, Strasbourg)
  Translational development of the next generation of poxvirus-based immunotherapeutics

12:45 **Lunch**

14:00 **Session 6: Targeting the tumor microenvironment for cancer immunotherapy**

Chairwoman/man: Christophe Caux (CRCL, Lyon) and Lucie Peduto (Institut Pasteur, Paris)

- 14:00-14:30 Vincenzo Bronté (VIMM, Padova)
  Alteration of monocyte survival and immune dysfunctions in cancer

- 14:30-15:00 Michele De Palma (EPFL, Lausanne)
  Reprogramming the immunosuppressive tumor microenvironment

15:00 **Coffee break**
15:30  **Session 7: Microbiota / Metabolism**  
Chairmen: François Vallette (CRCNA, Nantes) and Marc Bonneville (Institut Mérieux, Lyon)

- 15:30-16:00 Thomas Gajewski (University of Chicago, Chicago)  
  Tumor and host factors regulating anti-tumor immunity and immunotherapy efficacy

- 16:00-16:30 Laurence Zitvogel (Gustave Roussy, Villejuif)  
  The gut microbiome in cancer therapy

- 16:30-17:00 Christoph Hess (University of Basel, Switzerland)  
  Metabolic reprogramming enabling rapid CD8 T cell recall responses

17:00  **Round table on latest discovery and development strategies in cancer immunotherapy**  
Chairwoman/men: Jean-Pierre Abastado, Marc Bonneville, Leila Delamarre and Éric Quemeneur

18:00  **Concluding Remarks:**  
Claude Leclerc, Salem Chouaib and Christine Chomienne

**Conference website**  
www.cancer-immunotherapy2017.com

**Contact information:** immunotherapy2017@institutcancer.fr